Skip to main content
Premium Trial:

Request an Annual Quote

Former Perkin-Elmer COO Launches Discovery Co.


LA JOLLA, Calif.--A new company launched by Riccardo Pigliucci, former CEO of Life Sciences International and past president and chief operating officer of Perkin-Elmer, claimed it will create a new paradigm for serving the drug discovery needs of pharmaceutical companies. Discovery Partners International says it will form partnerships with pharmaceutical and biotech companies to foster the development of new technologies.

Pigliucci commented, "Most drug discovery platform companies have turned to developing their own lead compounds. We'll maintain our focus on the development of novel drug discovery platforms through funding or acquisition of companies with leading-edge or complementary technologies."

The first businesses brought under Discovery Partners' umbrella are Irori, a combinatorial chemistry company, and ChemRx, a new firm providing primary lead discovery chemical libraries and lead-optimization services using Irori's technology. Platform and service companies focusing on bioinformatics and screening technologies will be added in the near future, Pigliucci asserted.

Filed under

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.